コンテンツへスキップ
Merck
  • Cardiomyocytes stimulate angiogenesis after ischemic injury in a ZEB2-dependent manner.

Cardiomyocytes stimulate angiogenesis after ischemic injury in a ZEB2-dependent manner.

Nature communications (2021-01-06)
Monika M Gladka, Arwa Kohela, Bas Molenaar, Danielle Versteeg, Lieneke Kooijman, Jantine Monshouwer-Kloots, Veerle Kremer, Harmjan R Vos, Manon M H Huibers, Jody J Haigh, Danny Huylebroeck, Reinier A Boon, Mauro Giacca, Eva van Rooij
要旨

The disruption in blood supply due to myocardial infarction is a critical determinant for infarct size and subsequent deterioration in function. The identification of factors that enhance cardiac repair by the restoration of the vascular network is, therefore, of great significance. Here, we show that the transcription factor Zinc finger E-box-binding homeobox 2 (ZEB2) is increased in stressed cardiomyocytes and induces a cardioprotective cross-talk between cardiomyocytes and endothelial cells to enhance angiogenesis after ischemia. Single-cell sequencing indicates ZEB2 to be enriched in injured cardiomyocytes. Cardiomyocyte-specific deletion of ZEB2 results in impaired cardiac contractility and infarct healing post-myocardial infarction (post-MI), while cardiomyocyte-specific ZEB2 overexpression improves cardiomyocyte survival and cardiac function. We identified Thymosin β4 (TMSB4) and Prothymosin α (PTMA) as main paracrine factors released from cardiomyocytes to stimulate angiogenesis by enhancing endothelial cell migration, and whose regulation is validated in our in vivo models. Therapeutic delivery of ZEB2 to cardiomyocytes in the infarcted heart induces the expression of TMSB4 and PTMA, which enhances angiogenesis and prevents cardiac dysfunction. These findings reveal ZEB2 as a beneficial factor during ischemic injury, which may hold promise for the identification of new therapies.

材料
製品番号
ブランド
製品内容

Roche
cOmplete、ミニ、EDTA フリー、プロテアーゼ阻害剤カクテル, Protease Inhibitor Cocktail Tablets provided in a glass vial, Tablets provided in a glass vial
Sigma-Aldrich
ウシ胎児血清, non-USA origin, sterile-filtered, suitable for cell culture
Millipore
抗-FLAG® M2磁性ビーズ, affinity isolated antibody
Sigma-Aldrich
モノクローナル抗FLAG® M2抗体 マウス宿主抗体, clone M2, purified immunoglobulin (Purified IgG1 subclass), buffered aqueous solution (10 mM sodium phosphate, 150 mM NaCl, pH 7.4, containing 0.02% sodium azide)
Sigma-Aldrich
L-アスコルビン酸 2-リン酸 セスキマグネシウム塩 水和物, ≥95%
Sigma-Aldrich
3×FLAG®ペプチド, lyophilized powder
Sigma-Aldrich
アルブミン ヒト, Cellastim S, recombinant, expressed in rice, lyophilized powder, suitable for cell culture, low endotoxin, ≥96% (SDS-PAGE)
Sigma-Aldrich
ゼラチン from cold water fish skin, 40-50% in H2O
Sigma-Aldrich
抗グリセルアルデヒド-3-リン酸デヒドロゲナーゼ抗体、クローン6C5, clone 6C5, Chemicon®, from mouse
Sigma-Aldrich
DL-乳酸ナトリウム 溶液, BioReagent, syrup, 60 % (w/w), synthetic, suitable for cell culture
Sigma-Aldrich
レクチン コムギ胚芽(Triticum vulgaris)由来, FITC conjugate, lyophilized powder
Sigma-Aldrich
抗-α-アクチン(サルコメア)抗体、マウスモノクローナル, clone EA-53, purified from hybridoma cell culture
Sigma-Aldrich
Wnt Antagonist II, IWP-2, The Wnt Antagonist II, IWP-2, also referenced under CAS 686770-61-6, controls the biological activity of Wnt. This small molecule/inhibitor is primarily used for Cancer applications.
Sigma-Aldrich
GSK-3 Inhibitor XVI, GSK-3 Inhibitor XVI - CAS 252917-06-9, is a cell-permeable, potent, ATP-competitive, and highly selective GSK-3 inhibitor (IC₅₀ = 10 and 6.7 nM against GSK-3α and GSK-3β, respectively).
Sigma-Aldrich
抗ACTN2 ウサギ宿主抗体, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution